Patent details

EP2945626 Title: USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY

Basic Information

Publication number:
EP2945626
PCT Application Number:
IB2013050368
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP137055919
PCT Publication Number:
WO2014111751
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY
French Title of Invention:
UTILISATION D'AGONISTES DU RÉCEPTEUR NICOTINIQUE ALPHA 7 POUR LE TRAITEMENT DE LA NARCOLEPSIE
German Title of Invention:
VERWENDUNG VON ALPHA-7-NIKOTINREZEPTOR-AGONISTEN ZUR BEHANDLUNG VON NARKOLEPSIE
SPC Number:

Dates

Filing date:
15/01/2013
Grant date:
12/09/2018
EP Publication Date:
25/11/2015
PCT Publication Date:
24/07/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
12/09/2018
EP B1 Publication Date:
12/09/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
15/01/2019
Expiration date:
15/01/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
05/09/2018
 
 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:
FENDT, Markus
Address:
Switzerland (CH)

2

Name:
LOPEZ-LOPEZ, Cristina
Address:
Switzerland (CH)

3

Name:
FEUERBACH, Dominik
Address:
Switzerland (CH)

4

Name:
MCALLISTER, Kevin Hall
Address:
Switzerland (CH)

5

Name:
GOMEZ-MANCILLA, Baltazar
Address:
Switzerland (CH)

Classification

IPC classification:
A61K 31/439; A61K 31/46; A61P 25/20;

Publication

European Patent Bulletin

Issue number:
201837
Publication date:
12/09/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
31/05/2019 Outgoing Correspondence 1